News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,317 Results
Type
Article (43595)
Company Profile (277)
Press Release (694429)
Multimedia
Podcasts (110)
Webinars (21)
Section
Business (207578)
Career Advice (2089)
Deals (35993)
Drug Delivery (133)
Drug Development (82077)
Employer Resources (174)
FDA (16669)
Job Trends (15265)
News (351275)
Policy (33425)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2679)
Academic (1)
Accelerated approval (43)
Adcomms (25)
Allergies (165)
Alliances (50589)
ALS (198)
Alzheimer's disease (1770)
Antibody-drug conjugate (ADC) (395)
Approvals (17003)
Artificial intelligence (620)
Autoimmune disease (236)
Automation (53)
Bankruptcy (366)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (208)
Biotechnology (178)
Bladder cancer (179)
Brain cancer (67)
Breast cancer (699)
Cancer (5475)
Cardiovascular disease (458)
Career advice (1771)
Career pathing (42)
CAR-T (305)
CDC (55)
Celiac Disease (2)
Cell therapy (813)
Cervical cancer (44)
Clinical research (70746)
Collaboration (1991)
Company closure (4)
Compensation (1305)
Complete response letters (74)
COVID-19 (2795)
CRISPR (102)
C-suite (1033)
Cystic fibrosis (149)
Data (7242)
Decentralized trials (3)
Denatured (48)
Depression (155)
Dermatology (70)
Diabetes (554)
Diagnostics (7050)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (311)
Drug pricing (198)
Drug shortages (31)
Duchenne muscular dystrophy (268)
Earnings (91726)
Editorial (62)
Employer branding (22)
Employer resources (153)
Events (119605)
Executive appointments (1055)
FDA (20185)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1665)
Gene editing (219)
Generative AI (57)
Gene therapy (664)
GLP-1 (1039)
Government (4766)
Grass and pollen (6)
Guidances (400)
Healthcare (19135)
HIV (77)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (277)
Immuno-oncology (85)
Indications (163)
Infectious disease (3126)
Inflammatory bowel disease (203)
Inflation Reduction Act (16)
Influenza (133)
Intellectual property (278)
Interviews (322)
IPO (16743)
IRA (52)
Job creations (3846)
Job search strategy (1479)
JPM (62)
Kidney cancer (18)
Labor market (94)
Layoffs (565)
Leadership (36)
Legal (8174)
Liver cancer (98)
Longevity (29)
Lung cancer (734)
Lymphoma (411)
Machine learning (54)
Management (59)
Manufacturing (961)
MASH (179)
Medical device (13962)
Medtech (14044)
Mergers & acquisitions (20432)
Metabolic disorders (1433)
mRNA (184)
Multiple sclerosis (178)
NASH (18)
Neurodegenerative disease (388)
Neuropsychiatric disorders (97)
Neuroscience (3197)
Neurotech (1)
NextGen: Class of 2026 (6584)
Non-profit (4590)
Now hiring (74)
Obesity (676)
Opinion (290)
Ovarian cancer (197)
Pain (237)
Pancreatic cancer (267)
Parkinson's disease (348)
Partnered (34)
Patents (564)
Patient recruitment (615)
Peanut (61)
People (60246)
Pharmaceutical (60)
Pharmacy benefit managers (32)
Phase 1 (22047)
Phase 2 (31100)
Phase 3 (23205)
Pipeline (7475)
Policy (310)
Postmarket research (2620)
Preclinical (9432)
Press Release (67)
Prostate cancer (282)
Psychedelics (49)
Radiopharmaceuticals (314)
Rare diseases (1008)
Real estate (6211)
Recruiting (71)
Regulatory (25512)
Reports (54)
Research institute (2479)
Resumes & cover letters (363)
Rett syndrome (33)
RNA editing (20)
RSV (88)
Schizophrenia (168)
Series A (273)
Series B (205)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3685)
State (2)
Stomach cancer (18)
Supply chain (129)
Tariffs (87)
The Weekly (60)
Vaccines (1078)
Venture capital (103)
Weight loss (434)
Women's health (114)
Worklife (20)
Date
Today (123)
Last 7 days (613)
Last 30 days (2593)
Last 365 days (30258)
2026 (9151)
2025 (30336)
2024 (35442)
2023 (40365)
2022 (51479)
2021 (56085)
2020 (54545)
2019 (47055)
2018 (35410)
2017 (32600)
2016 (32076)
2015 (38092)
2014 (32004)
2013 (27149)
2012 (29221)
2011 (29926)
2010 (27991)
Location
Africa (773)
Alabama (91)
Alaska (7)
Arizona (338)
Arkansas (14)
Asia (40555)
Australia (6675)
California (12516)
Canada (3591)
China (1264)
Colorado (538)
Connecticut (542)
Delaware (376)
Europe (88419)
Florida (1885)
Georgia (403)
Hawaii (3)
Idaho (62)
Illinois (996)
India (84)
Indiana (577)
Iowa (22)
Japan (504)
Kansas (130)
Kentucky (47)
Louisiana (38)
Maine (75)
Maryland (1510)
Massachusetts (8952)
Michigan (349)
Minnesota (691)
Mississippi (6)
Missouri (151)
Montana (36)
Nebraska (29)
Nevada (139)
New Hampshire (84)
New Jersey (3336)
New Mexico (29)
New York (3305)
North Carolina (1604)
North Dakota (8)
Northern California (6192)
Ohio (383)
Oklahoma (23)
Oregon (42)
Pennsylvania (2537)
Puerto Rico (28)
Rhode Island (51)
South America (1150)
South Carolina (83)
South Dakota (2)
Southern California (4933)
Tennessee (201)
Texas (1981)
United States (44418)
Utah (379)
Vermont (1)
Virginia (296)
Washington D.C. (80)
Washington State (1007)
West Virginia (4)
Wisconsin (121)
Wyoming (2)
738,317 Results for "upsher smith laboratories inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
UPSHER-SMITH LAUNCHES GENERIC VERSION OF CIPRODEX® (CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1%) STERILE OTIC SUSPENSION
April 7, 2026
·
2 min read
Press Releases
UPSHER-SMITH LAUNCHES KYMBEE™ (DEFLAZACORT) TABLETS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
December 2, 2025
·
6 min read
Press Releases
UPSHER-SMITH ADDS DIFLUPREDNATE OPHTHALMIC EMULSION TO ITS GENERICS PORTFOLIO
September 18, 2025
·
2 min read
BioMidwest
UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg. The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according to IQVIA.
March 29, 2024
·
1 min read
Press Releases
Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
August 6, 2025
·
2 min read
BioMidwest
UPSHER-SMITH PREVIEWS EXPANSION OF ITS RARE DISEASE PORTFOLIO AT 2024 AAN ANNUAL MEETING
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, from April 13 to 18, 2024.
April 12, 2024
·
8 min read
Press Releases
PANTHERx® Rare Selected by Upsher-Smith Laboratories, LLC as Specialty Pharmacy for VIGAFYDE™ (vigabatrin) Oral Solution
March 25, 2025
·
3 min read
BioMidwest
UPSHER-SMITH LAUNCHES PITAVASTATIN TABLETS
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths.
November 6, 2023
·
1 min read
BioMidwest
UPSHER-SMITH LAUNCHES FAMOTIDINE FOR ORAL SUSPENSION, USP
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Famotidine for Oral Suspension, USP.
August 15, 2023
·
1 min read
Deals
CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M
Taiwanese contract development and manufacturing organization Bora will purchase Minnesota-based Upsher-Smith Laboratories, expanding operations into the U.S. for the first time.
January 18, 2024
·
2 min read
·
Tyler Patchen
1 of 73,832
Next
